New Opioid Bill Adds Requirements for Doctors
The Senate Health and Human Services committee has approved a bill that requires physicians to use the Prescription Drug Monitoring Program (PDMP). According to The Washington Times, the proposal squeezed by in a tight vote and will now go to the full Senate for a vote. The bill aims to identify and weed out physicians who overprescribe opioids and to prevent consumers from doctor shopping to gain access to opioids. Pharmacists have been required to participate in the PDMP for years, although enrollment for physicians had been voluntary.
12.2 Million People Sign Up for ACA Plans
Despite uncertainty surrounding the future of the Affordable Care Act (ACA) and the Trump administration’s decision to cancel last-minute ads, more than 12.2 million people signed up for coverage under the ACA. However, initial enrollment is still about 4% lower than last year. Nearly two-thirds of those who enrolled live in states that President Donald Trump carried. In Minnesota, a record number of people signed up through the state’s exchange. Although Minnesota had some of the sharpest premium increases for 2017, the state tapped a rainy day fund to help offset those rising premiums for people who weren’t eligible for federal subsidies.
Federal Government Ordered to Fund Risk Corridors
A Court of Federal Appeals has ruled in favor of an Oregon insurer, who sued the United States to recover money it was owed under the risk corridor program. The program protects insurers from excessive losses on the ACA exchanges. In a post for the Incidental Economist, Nicholas Bagley, JD, wrote that the ruling was the right one and that the court’s reasoning means every insurer can sue to recover risk corridor money. The government already owes $8.3 billion and the total liability could get close to $15 billion.
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More
Bustling Gene Therapy Pipeline for Neuromuscular Diseases Brings Thorny Questions to the Clinic
March 18th 2025The rapid development of gene therapy options for treating neuromuscular diseases has created new therapeutic options but also logistical hurdles and a need for complex discussions between clinicians and families.
Read More